Member Info for mol42

Website here

https://dermatonicsusa.com

mol

Who are they you might ask

well they operate in Trinidad and Tobago and they had a recent promotion (back in Mar 26) in their stores for Dermatonics products

Come In-Store to experience SAMPLING for Dermatonics

Products are safe for diabetics and specifically formulated to pamper feet and hands back to life.

What is even more amazing?

Whilst the promotion is happening in-store, customers would have the opportunity to get a Free product once they purchase any Dermatonics (receipt must be shown).

https://www.instagram.com/p/DVeYtqsEW8E/

mol

Plenty of recent activity here

https://www.facebook.com/AxisBiotix/

mol

Oops meant to post source

https://www.linkedin.com/posts/weareaubergine_what-a-week-activity-7460063741561204737-Di2M

mol

The mention may be in this article

https://www.thesun.co.uk/health/38846121/foods-making-skin-itchy-rashes/

mol

Apparently the drone stunt

https://weareaubergine.com/blog/2026/3/30/axisbiotix-drinkable-skincare-launch

has also recently secured an article in the Sun online

4 w

Big media moments this week for two of our brilliant clients 👏

📰 A double page spread in the Daily Express and Daily Mirror for the upcoming Cecil Beaton exhibition at Harewood House @harewoodhouse

🥑 National feature coverage in The Sun online with expert comment for AxisBiotix on itchy foods and skin health trends. @axisbiotix

At Aubergine, this is exactly what we do best - turning expert insight, culture and creativity into standout national coverage.

As former BBC and Channel 4 News journalists turned PR specialists, we know what makes a story land. From arts and culture to health, food, lifestyle and sustainability, we help brands cut through with journalist-led storytelling that gets results.

We’re proud to be the agency behind campaigns that consistently secure national headlines, features and conversations that matter.

https://www.instagram.com/p/DYO_928DF0L/

I cannot find said article so far but perhaps someone else can

mol

Dermatonics has also, at the start of last year, partnered with surefit in the USA

https://www.youtube.com/watch?v=4ZvaJx9wwJY

mol

Many thanks aquae and at least we now know the identity of a major customer whereas previously they weren’t disclosed - just a throwaway line that we weren’t reliant on any individual major customer.

mol

Anyone explain this note

3.4 Major Customers

Revenue from one external customer of the Products segment amounted to £386,274 (2024: £369,130), representing

approximately 16.4% of the Group’s total revenue.

No other single customer accounted for 10% or more of Group revenue during the half year.

In restated FY25 one external customer, Neon, within the Products segment, amounted to £801,604 (2024: £411,779)

which is 17.3% of the Group’s total revenue.

In restated FY25, no other single customer accounted for 10% or more of Group revenue during the year.

and is neon this company

https://neonhealthcare.com

mol

No problem aquae you have your view I have mine

bw

mol

Alyson

8 June

However, matters in relation to the CEO's conduct, which came to light as a result of the diligence and professional integrity of our CFO Emily Bertram, identifying and escalating issues to the Board, allowed us to act as swiftly as we did. This resulted in doubts concerning the validity of the FY25 financial statements.

16 February 2026 - the Board of SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, received information late on Friday 13 February 2026 that has informed its ongoing investigation into the conduct of the former CEO.

Over recent days, the Board has been urgently conducting an investigation of the business ("the Board Investigation"), following initial concerns over matters of conduct by the former CEO, who was first suspended and who has since resigned [Release link]. In addition to the initial concerns around his conduct, in light of the newly available information, the Board has reason to believe that the former CEO has misrepresented material information to the Board and senior management, the Company's auditors and advisors. The former CEO was informed of these allegations on Sunday 15 February 2026 and the Board Investigation is continuing. The Company has reported the Board's findings so far to the Company's auditors.

Information received late on Friday 13 February 2026 has cast significant doubt on the validity of the accrued royalty income recorded in the audited accounts for the year ended 30 June 2025 ("FY25 Accrued Royalty Income"). The Board currently expects that the FY25 Accrued Royalty Income, which amounted to £0.77m, will be removed from the FY25 accounts, subject to confirmation by the Company's auditors. The Board is confident, however, in the underlying financial health of the business due to its robust cash position (£2.92m as at 13 February 2026).

seems obvious to me but if you think she came forward earlier then who came forward late on Friday and why was it necessary to state same if they knew earlier, if disclosed by Emily as you appear to assert, and if it was someone else then why didn't Emily know or disclose or perhaps you think she raised initial concerns - a possibility- but not the financial irregularities until late Friday.

mol

At least the Board has now been updated on our website

https://www.skinbiotherapeutics.com/team//

mol

As far as I'm concerned an aggregate c£700k spent on outside firms and incurred on Director and Staff time on the investigation is well over the top and Emily of course only came forward late on the Friday after Ashman had resigned.

The jury is out for me regarding our new BOD going forward as if that is the control exercised over expenditure it doesn't augur well.

However as most here I'll wait a number of months before deciding my next step and I will be very interested in the salaries paid - they should be nowhere near what was paid previously albeit we will have to wait to end of year to get individual breakdown - mind in the name of corporate governance why not disclose now Alyson

mol

The actual RNS states

To date, the costs of the Board Investigation are in aggregate c.£0.7m. The Board will be pursuing recovery of costs incurred in connection with the investigation and any other losses through ongoing legal proceedings and will update shareholders as those matters progress

Whilst Alyson within her report drops the in aggregate

he Board has, throughout, been very conscious that the costs of such investigations can escalate quickly and has therefore sought to balance the need for a comprehensive investigation with the cost/risk benefit, to give maximum confidence that any and all relevant issues have been identified and addressed. To date, the costs of the investigation have come to c.£0.70m. The Board will be pursuing recovery of costs incurred in connection with the investigation and any other losses through ongoing legal proceedings and will update shareholders as those matters progress.

And both state circa 700k

I take the RNS to be more accurate and assume cost of c700k includes management time auditor time staff time in addition to FRP’s bill

mol

As at 08 June 2026

Number Ordinary Shares %

Mark and Diana Dixon 69,900,000 26.97%

David Brierwood 16,539,989 6.38%

Tyndall Investment Management 15,223,381 5.87%

Seneca Partners Limited 8,409,913 3.24%

Unicorn Asset Management 7,894,737 3.05%

obviously the Director shareholdings, as previously disclosed, are no longer listed as they are no longer Directors rather than they have sold - we will never know

Previously

As at 01 April 2026 significant shareholders that hold more than 3% of the share capital of SkinBioTherapeutics plc are detailed below:

Number Ordinary Shares - %

Mark and Diana Dixon 61,000,000 23.54%

David Brierwood 16,389,989 6.32%

Tyndall Investment Management 15,223,381 5.87%

OptiBiotix Health Plc 14,600,000 5.63%

Seneca Partners Limited 10,561,405 4.08%

Unicorn Asset Management 7,894,737 3.05%

Director Shareholders

Number Ordinary Shares %

Martin Hunt* 560,417 0.22%

Dr Cathy Prescott 181,112 0.07%

mol

This isn't going to change

The Directors received the following remuneration during the year:

SA £307,570 and pension £9,162

MR £188,572 and pension £5,572 (11 months)

SH £25,416 and pension £ £1,226. - (one month)

Non Exec

MH £14,378 and fees £57,511

CP £7,189 and fees ££28,715

DB £27,165

The salaries going forward should be nowhere near these figures but will take to release of June 2026 for us to find out ie towards end of this year

Don't be surprised at the level paid by our company on the aim gravy chain though - I won't be- but very surprised should at least 50% less paid for executives - at which level I think more than adequately remunerated for level of turnover etc

mol

Https://www.psoriasis-association.org.uk/forums/topic.aspx?ID=7821

Posted Thu 16 Apr 2026 20.21 by TINA

I have been taking Axisbiotix for over a year and cannot claim any quick or massive improvement in my psoriasis. I can say that I have had psoriasis constantly for over 60 years now, always pretty badly and several times erythrodermic. It is much better now, and still improving slowly, which could be due to several factors: Could be the Axisbiotix or it could be eating blueberries and replacing cow's milk products with goats milk, cheese and yoghurt. Also cut out alchohol and having kept a food diary, eating a fodmap diet as much as possible. I have recently started using goats yoghurt topically and it definately soothes any very red and itchy patches, which again are reducing slowly.

I am certainly continuing with the Axisbiotix for the present, as I think, combined with the other measures mentioned above, that it is helping with a slow improvement. Also I think it helps with my digestive problems. If you can afford it, there doesn't seem to be anything to lose by trying it.

we can only hope she is not lambasted by some of the posters who seem to delight in responding, even at that website, to anything concerning axisbiotix

and its possible benefits to a very distressing condition

mol

Apparently this site was set up last year but not impressive at all - not sure who was behind same albeit NZ Manuka honey is the reason

http://pheet.co.nz

the advertised price to buy is NZ$ 0.00 or even two at NZ$ 0.00

bargain methinks

mol

Indeed rebarm

and the fact it was also posted (no longer accepting applications btw) by alera advisory owned, run and only employee by Rachel our interim CEO now appointed to the board is also a concern

not off to a good start imo and to date I have had little faith in Emily's performance as company secretary prior to her appointment to the board and again why we need two qualified accountants is beyond me nevermind presumably the bookkeepers behind the scenes

and anyone expecting a detailed explanation regarding the circumstances behind our ex CEO's resignation will be sorely disappointed if legal action is either contemplated or has been started - which again reinforces the view held by a number here that time is up and has been for weeks regarding the release of the amended 6 monthly statements

mol

Maternity Cover (12 months)

Newcastle HQ (hybrid)

Are you a strategic, hands-on marketer with a passion for brands and customer experience? We're looking for an exceptional individual to join the SkinBioTherapeutics group on a 12-month maternity cover, taking ownership of marketing, customer service and brand communications across our growing portfolio of science-backed skin health brands.

This is a rare, high-impact role that spans the full breadth of our business from digital campaigns and brand development to B2B customer service and PLC-level communications.

About Us

SkinBioTherapeutics is a life science company advancing skin health from the inside out and outside in. Our portfolio spans topical innovations — including Zenakine, the world's first neurocosmetic ingredient, and Dermatonics, a clinically supported foot and hand care range — plus AxisBiotix, a food supplement supporting the gut–skin axis. Backed by in-house manufacturing and scientific discovery, we move efficiently from concept to commercialisation.

The Role

Working across multiple brands, you'll lead marketing strategy and execution, oversee B2B and B2C customer service, and manage corporate communications for our PLC. You'll be supported by a marketing assistant and work closely with finance, sales, agencies and subsidiaries.

What You'll Do

Brand & Marketing

Oversee brand refresh rollout, updating POS, guidelines and marketing collateral

Provide retail, online and wholesale channels with relevant brand materials

Lead integrated marketing campaigns across social, email, paid and brand channels

Establish and maintain a corporate communications calendar across the group

Manage Meta and Google advertising — optimising spend and creative performance

Drive online revenue across websites and Amazon

Coordinate NPD pipeline activity

Customer Service & Experience

Manage B2B and consumer customer service queries across all brands

Improve efficiency across customer service and marketing workflows

Enhance engagement for B2B customers and consumers

Manage Trustpilot reviews and overall customer sentiment

PLC Communications

Manage SkinBioTherapeutics LinkedIn content and corporate communications

Support the preparation and distribution of PLC-level updates and announcements

mol